These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 17630049)

  • 1. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands.
    Boot HJ; Wallenburg I; de Melker HE; Mangen MJ; Gerritsen AA; van der Maas NA; Berkhof J; Meijer CJ; Kimman TG
    Vaccine; 2007 Aug; 25(33):6245-56. PubMed ID: 17630049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Insufficient basis for the inclusion of Human papillomavirus vaccination in the National Immunisation Programme in The Netherlands].
    de Kok IM; Habbema JD; Mourits MJ; Coebergh JW; van Leeuwen FE
    Ned Tijdschr Geneeskd; 2008 Sep; 152(37):2001-4. PubMed ID: 18825885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM; van Ballegooijen M; Habbema JD
    J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vaccines against human papillomavirus (HPV); between registration and implementation].
    van Rossum TG; de Melker HE; Houweling H; Voordouw AC; Meijer CJ; Helmerhorst TJ; Kretzschmar M; Berkhof J; van der Noordaa J
    Ned Tijdschr Geneeskd; 2008 Apr; 152(17):987-92. PubMed ID: 18549172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands.
    Bogaards JA; Coupé VM; Meijer CJ; Berkhof J
    Vaccine; 2011 Nov; 29(48):8929-36. PubMed ID: 21945961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].
    Westra TA; Daemen T; Postma MJ; Wilschut JC
    Ned Tijdschr Geneeskd; 2009; 153():A356. PubMed ID: 19930733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
    Adams M; Jasani B; Fiander A
    Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands.
    Rogoza RM; Westra TA; Ferko N; Tamminga JJ; Drummond MF; Daemen T; Wilschut JC; Postma MJ
    Vaccine; 2009 Jul; 27(35):4776-83. PubMed ID: 19539578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention.
    Garland SM; Brotherton JM; Skinner SR; Pitts M; Saville M; Mola G; Jones RW
    Vaccine; 2008 Aug; 26 Suppl 12():M80-8. PubMed ID: 18945417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
    Barnabas RV; Laukkanen P; Koskela P; Kontula O; Lehtinen M; Garnett GP
    PLoS Med; 2006 May; 3(5):e138. PubMed ID: 16573364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
    Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
    Schneider A; Schwarz TF; Hammerschmidt T; Siebert U
    Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence.
    Bogaards JA; Coupé VM; Xiridou M; Meijer CJ; Wallinga J; Berkhof J
    Epidemiology; 2011 Jul; 22(4):505-15. PubMed ID: 21540743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Vaccination against human papillomavirus for the prevention of cervical cancer].
    Quint WG; ter Harmsel WA; van Doorn LJ
    Ned Tijdschr Geneeskd; 2006 Jun; 150(25):1380-4. PubMed ID: 16841585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of human papilloma virus vaccination in Iceland.
    Oddsson K; Johannsson J; Asgeirsdottir TL; Gudnason T
    Acta Obstet Gynecol Scand; 2009; 88(12):1411-6. PubMed ID: 19900074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands.
    Coupé VM; de Melker HE; Snijders PJ; Meijer CJ; Berkhof J
    Vaccine; 2009 Aug; 27(37):5111-9. PubMed ID: 19567242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus vaccines: an update for gynecologists.
    Ault KA
    Clin Obstet Gynecol; 2008 Sep; 51(3):527-32. PubMed ID: 18677145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness?
    de Kok IM; Habbema JD; van Rosmalen J; van Ballegooijen M
    Eur J Cancer; 2011 Feb; 47(3):428-35. PubMed ID: 20971633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human papillomavirus (HPV) vaccines: a Canadian update.
    Foerster V; Murtagh J
    Issues Emerg Health Technol; 2007 Dec; (109):1-8. PubMed ID: 18062141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing.
    Schiffman M
    Cancer; 2007 Jun; 111(3):145-53. PubMed ID: 17487850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.